| Literature DB >> 19208201 |
Camille C Ragin1, Robert P Edwards, Jade Jones, Natalie E Thurman, Kourtney L Hagan, Erin A Jones, Cierra M Moss, Ar'lena C Smith, Aletha Akers, Susanne M Gollin, Dwight E Heron, Cecile Andraos-Selim, Cornelius Bondzi, Linda Robertson, Emanuela Taioli.
Abstract
BACKGROUND: The United States (US) Food & Drug Administration (FDA) recently approved a human papillomavirus (HPV) vaccine with the purpose of reducing the risk of cervical cancers caused by HPV 16 and HPV 18. It is important that the general population be educated about HPV and the HPV vaccine in order to make the appropriate decision whether or not to vaccinate against this virus. Participants from the adult US general population of Pittsburgh, Pennsylvania, USA and Hampton, Virginia, USA (18+ years old) were surveyed to determine their knowledge about HPV and the HPV vaccine, and to evaluate their perception of the vaccine efficacy and safety.Entities:
Year: 2009 PMID: 19208201 PMCID: PMC2638455 DOI: 10.1186/1750-9378-4-S1-S10
Source DB: PubMed Journal: Infect Agent Cancer ISSN: 1750-9378 Impact factor: 2.965
Description of the studied populations according to race
| 202 (100) | 89 (44.5) | 109 (54.5) | 2 (1.0) | ||
| Hampton, VA | 76 (37.6) | 68 (76.4) | 7 (6.4) | 1 (50.0) | 0.0001 |
| Pittsburgh, PA | 126 (62.4) | 21 (23.6) | 102 (93.6) | 1 (50.0) | <0.0001 |
| 18–35 | 90 (45) | 65 (73.9) | 24 (22.4) | 1 (50.0) | <0.0001 |
| 36–55 | 63 (32) | 20 (22.7) | 42 (39.3) | - | |
| 56+ | 45 (23) | 3 (3.4) | 41 (38.3) | 1 (50.0) | |
| Female | 143 (72.2) | 61 (69.3) | 80 (74.8) | 1 (50.0) | |
| Male | 55 (27.8) | 27 (30.7) | 27 (25.2) | 1 (50.0) | |
| Yes | 99 (49.0) | 28 (32.6) | 70 (64.2) | 1 (50.0) | 0.005 |
| Children (average no, range) | 2, 1–5 | 3, 1–5 | 2, 1–4 | 3 | 0.0001 |
| High school or less | 16 (8) | 9 (10.2) | 7 (6.4) | - | |
| Post-secondary education | 184 (92) | 79 (89.8) | 102 (93.6) | 2 (100.0) | |
| Less than $35,000 | 57 (31.5) | 32 (39.0) | 23 (24.0) | 1 (50.0) | |
| $25,000–$55,000 | 32 (17.7) | 15 (18.3) | 17 (17.7) | - | |
| Greater than $55,000 | 92 (50.8) | 35 (42.7) | 56 (58.3) | 1 (50.0) | |
| No | 12 (6.0) | 8 (9.0) | 3 (2.8) | 1 (50.0) | |
| Yes | 189 (94.0) | 81 (91.0) | 106 (97.2) | 1 (50.0) | |
| Christian | 150 (77.3) | 67 (79.8) | 82 (75.9) | 1 (50.0) | |
| Other | 28 (14.4) | 15 (17.9) | 12 (11.1) | 1 (50.0) | |
| None | 16 (8.3) | 2 (2.3) | 14 (13.0) | - | |
| Single | 96 (47.8) | 67 (75.3) | 27 (24.8) | 1 (50.0) | <0.0001 |
| Married | 77 (38.3) | 13 (14.6) | 63 (57.8) | 1 (50.0) | 0.006 |
| Other | 28 (13.9) | 9 (10.1) | 19 (17.4) | - | |
| No | 66 (33.3) | 26 (30.2) | 37 (33.9) | ||
| Yes | 131 (66.2) | 60 (69.8) | 71 (65.1) | ||
*p-value shown only when there is a statistically significant difference between Blacks vs. Whites; Race was not defined for 2 participants
Assessment of HPV knowledge: adjusted proportions of the correct answers by race
| Have you heard of the Human Papillomavirus (HPV)? | 89.3% (75.5%–95.8%) | 96.9% (90.6%–99.0%) | |
| HPV is not sexually transmitted | 63.9% (47.7%–77.4%) | 81.0% (69.6%–88.8%) | |
| HPV infection is relatively uncommon | 63.8% (47.6%–77.4%) | 87.7% (78.4%–93.3%) | 0.013 |
| HPV causes cervical cancer | 73.2% (57.2%–84.8%) | 90.7% (81.6%–95.5%) | 0.044 |
| Who can become infected with HPV? | 54.4% (38.7%–69.2%) | 65.1% (51.5%–76.6%) | |
| Both men and women can have cervical cancer | 83.6% (67.9%–92.5%) | 95.8% (87.4%–98.7%) | |
| The incidence of HPV in women is highest among women in their 20's and 30's | 69.2% (53.9%–81.2%) | 65.9% (52.2%–77.4%) | |
| Most people with genital HPV infections are symptomatic | 41.5% (26.5%–58.3%) | 73.6% (60.5%–83.5%) | 0.014 |
| HPV causes genital warts | 37.3% (24.1%–52.7%) | 51.7% (38.6%–64.5%) | |
| Genital warts are caused by the same HPV types that cause cervical cancer | 19.5% (10.3%–33.8%) | 16.5% (8.7%–28.9%) | |
| There is a cure for HPV infection | 47.6% (31.2%–64.6%) | 68.4% (54.3%–79.8%) |
*Proportions adjusted for location, age, education, income, parental status and marital status; p-value shown only when there is a statistically significant difference between Blacks and Whites.
Figure 1Cumulative distribution of the number of respondents who provided correct answers to the questions on the level of knowledge for (A) HPV and (B) the HPV vaccine.
Figure 2Distribution of the predicted number of correct answers to the 10 questions which assessed HPV knowledge, stratified by ethnicity and recruitment location and adjusted for age, education, income, parental status and marital status. The adjusted mean for each stratum is denoted by dashed lines.
Knowledge assessment of the HPV vaccine: adjusted proportions of the correct answers by race
| Have you heard about the HPV vaccine? | 76.4% (60.1%–87.4%) | 93.3% (84.9%–97.2%) | 0.031 |
| The HPV vaccine is approved for individuals who have never been infected with HPV | 48.8% (33.8%–64.0%) | 81.2% (69.9%–88.9) | 0.004 |
| Who is eligible for the HPV vaccine? | 63.7% (47.8%–77.1%) | 81.3% (69.2%–89.3%) | |
| For which age group is the HPV vaccine recommended? | 63.2% (46.6%–77.2%) | 89.5% (78.5%–95.2%) | 0.012 |
| The current FDA approved HPV vaccine protects against genital warts and most cervical cancer | 20.0% (10.0%–36.1%) | 16.1% (8.1%–29.3%) | |
| Once vaccinated women no longer have to be screened (annual pap smears) for cervical cancer | 78.9% (63.8%–88.8%) | 91.7% (82.7%–96.3%) |
*Proportions adjusted for location, age, education, income, parental status and marital status; p-value shown only when there is a statistically significant difference between Blacks and Whites.
Figure 3Distribution of the predicted number of number of correct answers to the five questions which assessed knowledge of the HPV vaccine, stratified by ethnicity and recruitment location and adjusted for age, education, income, parental status and marital status. The adjusted mean for the number of correct answers in each stratum is denoted by dashed lines.
Figure 4Participants' responses to questions that evaluated their perception of the HPV vaccine.